Tags

Type your tag names separated by a space and hit enter

[Investigation of hepatitis G virus prevalence in hemodialysis patients and blood donors in Denizli, Turkey].
Mikrobiyol Bul. 2008 Oct; 42(4):617-25.MB

Abstract

This study focuses on the prevalence of hepatitis G virus (GBV-C/HGV) in hemodialysis patients and blood donors in Denizli (located at Aegean region of Turkey). A total of 100 patients (mean age: 56.8 +/- 13.3 years; 46 female) receiving hemodialysis and 100 blood donors (mean age: 31.3 +/- 8.1 years; 8 female) were included in the study. The presence of GBV-C/HGV RNA was determined in all patients by reverse transcriptase-PCR and the presence of GBV-C/HGV anti-E2 antibodies was determined by a commercial enzyme immunoassay (Diagnostic Automation, INC). Viral RNA positivity was determined in 14 (14%) of the hemodialysis patients and 2 (2%) of the blood donors, the difference being statistically significant (p < 0.05). GBV-C/HGV anti-E2 antibodies were detected in 1 (1%) of the hemodialysis patients and 3 (3%) of the blood donors. Anti-E2 positive patient also revealed positive result for viral RNA. There was no statistically significant difference between the two groups in terms of anti-E2 positivity. The prevalence of GBV-C/HGV was 14% in hemodialysis patients and 5% in blood donors (p < 0.05). There was no significant difference in terms of duration of hemodialysis, serum ALT levels, age or gender between GBV-C/HGV positive and negative hemodialysis patients. In conclusion, since hemodialysis patients are at an increased risk of parenteral transmission, they have significantly higher GBV-C/HGV viremia rates and prevalence when compared to blood donors. However, the prevalence of GBV-C/HGV and coexistence between GBV-C/HGV and hepatitis C virus have been decreasing in our region owing to increased hygienic precautions in hemodialysis units, avoidance of unnecessary blood transfusions and more widespread use of erythropoietin.

Authors+Show Affiliations

Zonguldak Devlet Hastanesi, Mikrobiyoloji ve Klinik Mikrobiyoloji Kliniği, Zonguldak. mdsevgi@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

tur

PubMed ID

19149083

Citation

Hanci, Sevgi Yilmaz, et al. "[Investigation of Hepatitis G Virus Prevalence in Hemodialysis Patients and Blood Donors in Denizli, Turkey]." Mikrobiyoloji Bulteni, vol. 42, no. 4, 2008, pp. 617-25.
Hanci SY, Cevahir N, Kaleli I, et al. [Investigation of hepatitis G virus prevalence in hemodialysis patients and blood donors in Denizli, Turkey]. Mikrobiyol Bul. 2008;42(4):617-25.
Hanci, S. Y., Cevahir, N., Kaleli, I., & Hanci, V. (2008). [Investigation of hepatitis G virus prevalence in hemodialysis patients and blood donors in Denizli, Turkey]. Mikrobiyoloji Bulteni, 42(4), 617-25.
Hanci SY, et al. [Investigation of Hepatitis G Virus Prevalence in Hemodialysis Patients and Blood Donors in Denizli, Turkey]. Mikrobiyol Bul. 2008;42(4):617-25. PubMed PMID: 19149083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Investigation of hepatitis G virus prevalence in hemodialysis patients and blood donors in Denizli, Turkey]. AU - Hanci,Sevgi Yilmaz, AU - Cevahir,Nural, AU - Kaleli,Ilknur, AU - Hanci,Volkan, PY - 2009/1/20/entrez PY - 2009/1/20/pubmed PY - 2009/4/8/medline SP - 617 EP - 25 JF - Mikrobiyoloji bulteni JO - Mikrobiyol Bul VL - 42 IS - 4 N2 - This study focuses on the prevalence of hepatitis G virus (GBV-C/HGV) in hemodialysis patients and blood donors in Denizli (located at Aegean region of Turkey). A total of 100 patients (mean age: 56.8 +/- 13.3 years; 46 female) receiving hemodialysis and 100 blood donors (mean age: 31.3 +/- 8.1 years; 8 female) were included in the study. The presence of GBV-C/HGV RNA was determined in all patients by reverse transcriptase-PCR and the presence of GBV-C/HGV anti-E2 antibodies was determined by a commercial enzyme immunoassay (Diagnostic Automation, INC). Viral RNA positivity was determined in 14 (14%) of the hemodialysis patients and 2 (2%) of the blood donors, the difference being statistically significant (p < 0.05). GBV-C/HGV anti-E2 antibodies were detected in 1 (1%) of the hemodialysis patients and 3 (3%) of the blood donors. Anti-E2 positive patient also revealed positive result for viral RNA. There was no statistically significant difference between the two groups in terms of anti-E2 positivity. The prevalence of GBV-C/HGV was 14% in hemodialysis patients and 5% in blood donors (p < 0.05). There was no significant difference in terms of duration of hemodialysis, serum ALT levels, age or gender between GBV-C/HGV positive and negative hemodialysis patients. In conclusion, since hemodialysis patients are at an increased risk of parenteral transmission, they have significantly higher GBV-C/HGV viremia rates and prevalence when compared to blood donors. However, the prevalence of GBV-C/HGV and coexistence between GBV-C/HGV and hepatitis C virus have been decreasing in our region owing to increased hygienic precautions in hemodialysis units, avoidance of unnecessary blood transfusions and more widespread use of erythropoietin. SN - 0374-9096 UR - https://www.unboundmedicine.com/medline/citation/19149083/[Investigation_of_hepatitis_G_virus_prevalence_in_hemodialysis_patients_and_blood_donors_in_Denizli_Turkey]_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -